Rani Therapeutics Holdings (RANI) Receivables (2020 - 2025)
Rani Therapeutics Holdings' (RANI) quarterly Receivables came in at $2.0 million in Q4 2025, up 146.62% year-on-year from $828000.0 in Q4 2024, and up 240.33% quarter-over-quarter from $600000.0 in Q1 2025.
Rani Therapeutics Holdings (RANI) Receivables (2020 - 2025) Analysis & Trends
Rani Therapeutics Holdings' Receivables history runs 3 years deep, the most recent figure standing at $2.0 million for Q4 2025.
- On a quarterly basis, Receivables rose 146.62% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $2.0 million, a 146.62% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 146.62% from the prior year.
- Receivables rose to $2.0 million in Q4 2025 per RANI's latest filing, from $600000.0 in the prior quarter.
- Across five years, Receivables topped out at $2.0 million in Q4 2025 and bottomed at $600000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 828,000.00 |
| Dec 31, 2020 | 1.72 Mn |